Breaking News
November 16, 2018 - ACC Latin America Conference brings experts to discuss latest cardiovascular science
November 16, 2018 - Pooled analysis of Intersect ENT’s steroid releasing implants in patients after frontal sinus surgery to be published
November 16, 2018 - Expectations about pain intensity can become self-fulfilling prophecies
November 16, 2018 - NIH awards $3.4 million to UC researchers to study gastrointestinal lymphatic system
November 16, 2018 - Scientist Dr David Taylor of MR Solutions is a finalist in the BMW i UK Tech Founder Awards
November 16, 2018 - Earlier treatment could help reverse autistic-like behavior in tuberous sclerosis
November 16, 2018 - Vegetables and salad may include bacteria that are resistant to antibiotics
November 16, 2018 - Endocrine Society chooses four Diabetes Caucus leaders as winners of Diabetes Champion Award
November 16, 2018 - Brain and muscle cells found within kidney organoids
November 16, 2018 - Person’s sex hormones may play key role in trauma survival, finds study
November 16, 2018 - PTEN Genetic Test: MedlinePlus Lab Test Information
November 16, 2018 - Toxic metal pollution linked with development of autism spectrum disorder
November 16, 2018 - Calcified nodules in the retina increase risk for progression to late stages of AMD
November 16, 2018 - ZEISS teams up with arivis AG to offer complete 3D imaging solutions
November 16, 2018 - Georgia State professor receives $1.2 million grant to study how the brain controls eating behavior
November 16, 2018 - Specific bacterial toxins reduce number of cells suppressing immune response
November 16, 2018 - Review by ID physician improves outcomes for outpatient parenteral antimicrobial therapy
November 16, 2018 - Conditions that produce signs similar to arthritis
November 16, 2018 - AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
November 16, 2018 - Surgery remains best treatment for appendicitis, Stanford study finds
November 16, 2018 - Non-surgical fistula creation system Ellipsys becomes key focus of attention at CiDA
November 16, 2018 - Researchers find no link between ‘allergy friendly’ dogs and lower risk of asthma
November 16, 2018 - Researchers elucidate new rules of connectivity of neurons in the neocortex
November 16, 2018 - Treating children with ‘bubble baby disease’
November 16, 2018 - Nexus announces availability of Arsenic Trioxide Injection in the US
November 16, 2018 - Researchers find metabolite shuttle between cells in the liver that may combat tissue fibrosis
November 16, 2018 - AHA: PTSD Common Among Those Who Suffer Tear in the Aorta’s Wall
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
November 16, 2018 - Inexpensive, portable air purifier could help protect the heart from pollution
November 16, 2018 - New 15-minute scan could help diagnose brain damage in babies up to two years old
November 16, 2018 - Deep brain stimulation not effective for treating early Alzheimer’s
November 16, 2018 - Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
November 16, 2018 - What This Pond Protist Does With Its Genome Will Astound You
November 15, 2018 - Researchers develop tool that speeds up analysis and publication of biomedical data
November 15, 2018 - Scientists identify mechanism used by lung cancer cells to obtain glucose
November 15, 2018 - Abnormalities in development of the brain could be involved in onset of autism, finds new study
November 15, 2018 - Soy protein equally effective as animal protein in building muscle strength
November 15, 2018 - American Academy of Pediatrics, Nov. 2-6
November 15, 2018 - Dopamine drives early addiction to heroin
November 15, 2018 - Variance in gut microbiome in Himalayan populations linked to dietary lifestyle | News Center
November 15, 2018 - Reducing Cardiovascular Disease: The Amish Way
November 15, 2018 - King’s researchers launch charter to guide organizations to engage abuse survivors in research
November 15, 2018 - Enable Injections enters into development agreements with UCB and Apellis Pharmaceuticals
November 15, 2018 - TGen North collaborates with NARBHA Institute to advance human health
November 15, 2018 - Researchers discover molecular basis for therapeutic actions of an African folk medicine
November 15, 2018 - Human Cell Atlas study of early pregnancy shows how mother’s immune system is modified
November 15, 2018 - New guidelines for detecting and managing sarcopenia to be launched in the UK
November 15, 2018 - Researchers explore role of dietary composition on energy expenditure
November 15, 2018 - Elsevier launches Entellect™ Platform, unlocking value by creating AI-ready life sciences data
November 15, 2018 - Now that cannabis is legal in Canada, let’s use it to tackle the opioid crisis
November 15, 2018 - In the Spotlight: At the intersection of tech, health, and ethics
November 15, 2018 - Traditional Glaucoma Test Can Miss Severity of the Disease
November 15, 2018 - Researchers directly connect activities of genes with instinctive behavior in male cichlids
November 15, 2018 - Salk researchers report new methods to identify AD drug candidates with anti-aging properties
November 15, 2018 - St. Jude Hospital announces availability of largest collections of leukemia samples
November 15, 2018 - Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
November 15, 2018 - Designing a novel cell-permeable peptide chimera to promote wound healing
November 15, 2018 - NEI investigators combine two imaging modalities to view the retina in unprecedented detail
November 15, 2018 - Determining how hearts develop to better understand congenital heart defects
November 15, 2018 - Maverick immune cells can act independently to identify and kill cancer cells, finds research
November 15, 2018 - Advanced AI and big data methods to tackle dementia
November 15, 2018 - Report reveals increase in pancreatic cancer death rates across Europe
November 15, 2018 - Luxia Scientific announces availability of its gut microbiome test in Luxembourg
November 15, 2018 - New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis
November 15, 2018 - New approach targets matrix surrounding neurons to protect neurons after stroke
November 15, 2018 - Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine
November 15, 2018 - Heart failure patients shouldn’t stop meds even if condition improves: study
November 15, 2018 - Parents and carers of people with diabetes experience emotional or mental health problems
New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

image_pdfDownload PDFimage_print

A phase 2 clinical trial led by Stephanie N. Taylor, MD, Professor of Medicine and Microbiology in the Section of Infectious Diseases at LSU Health New Orleans School of Medicine, has found that a new antibiotic effectively treats uncomplicated urogenital and rectal gonorrhea infections in a single oral dose. Results are published in the November 8, 2018, issue of the New England Journal of Medicine.

“According to the Centers for Disease Control and Prevention, the incidence of gonorrhea in the US increased by 67% from 2013 to 2017,” notes Dr. Taylor. “The bacteria causing gonorrhea, Neisseria gonorrhoeae, has developed resistance to every class of antibiotic currently recommended for treatment, and reports of multidrug-resistant N. gonorrhoeae necessitate the urgent development of new antimicrobial agents.”

The researchers conducted a randomized, open-label phase 2 clinical trial to determine the safety and effectiveness of the investigational drug, zoliflodacin, in treating uncomplicated gonorrhea infections. Zoliflodacin, which has been fast-tracked by the FDA, works differently from the antibiotics currently available to treat gonorrhea. It inhibits DNA biosynthesis in a new way, impeding bacterial growth. Entasis Therapeutics in Waltham, MA developed zoliflodacin.With a goal of 144 participants with gonorrhea, a total of 179 participants were enrolled at sexual health clinics in New Orleans, Seattle, Indianapolis, Birmingham and Durham, North Carolina from November 2014 through December 2015. The men and non-pregnant women, 18 – 55 years old, were eligible if they had signs and symptoms of urogenital gonorrhea, untreated urogenital gonorrhea or sexual contact in the preceding 14 days with a person who had gonorrhea. Urethral, cervical, pharyngeal and rectal swabs were taken at enrollment. Thirty-eight participants were excluded due to negative cultures. Participants were randomly assigned to receive a single, oral dose of either 2 or 3 grams of zoliflodacin or a single injected dose of 500 mg of ceftriaxone, one of the two drugs currently used to treat gonorrhea.

The microbiologic intention-to-treat (micro-ITT) group (141 participants) included all participants with gonorrhea at urethral or cervical sites. The per-protocol group included the participants in the micro-ITT group who met all inclusion criteria, did not have another infection other than chlamydia or bacterial vaginosis, did not receive any other systemic antibiotic before test of cure and returned for a test-of-cure visit within a six-day window.

The primary measure of efficacy was the proportion of participants with urogenital infections who were cured. The secondary measure of effectiveness was the number of participants whose pharyngeal and rectal infections were cured. The primary safety outcome measure was the proportion of participants reporting adverse events.

Treatment with 2 or 3 g of zoliflodacin resulted in a 96% cure rate in those with urogenital infections in the micro-ITT group, while the cure rate for those treated with ceftriaxone was 100%. In the per-protocol group, 98% of the participants who took the 2-gram dose of zoliflodacin and 100% of those who received the 3-gram dose, as well as all of the participants in the ceftriaxone group, were cured. All of those with rectal infections who were treated regardless of dose or medication were cured. Pharyngeal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of zoliflodacin, and ceftriaxone, respectively.

A total of 21 adverse events were associated with zoliflodacin, mostly gastrointestinal. In the ceftriaxone group, 23 adverse events were reported.

“Ceftriaxone is one of two drugs used as the current standard of care to treat uncomplicated gonorrhea,” adds Taylor. “A cephalosporin, it is the last class of antibiotics we have to treat gonorrhea. While it has worked well, we are starting to see resistance to it, too. Since there is no vaccine to prevent gonorrhea, and the possibility of untreatable gonorrhea is looming larger, it is imperative that we develop new drugs to treat it. Our promising early results suggest that zoliflodacin could be one of them.”

According to the CDC, gonorrhea is the second most commonly reported notifiable disease in the United States. In 2017, a total of 555,608 cases of gonorrhea were reported in the United States. Louisiana ranks second in the nation with 257 cases per 100,000 people reported last year. Infections due to Neisseria gonorrhoeae are a major cause of pelvic inflammatory disease (PID) in the United States. PID can lead to serious outcomes in women, such as tubal infertility, ectopic pregnancy, and chronic pelvic pain. In addition, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.

Source:

https://www.lsuhsc.edu/newsroom/Study%20Finds%20New%20Single-Dose%20Antibiotic%20Safe%20and%20Effective%20for%20Uncomplicated%20Gonorrhea.html

Tagged with:

About author

Related Articles